FAQ: Propanc Biopharma's $4 Million Public Offering and Cancer Treatment Research

What is the main purpose of Propanc Biopharma’s public offering?

The public offering generated $4 million in gross proceeds to support the company’s development of novel pancreatic proenzyme therapies that target and eradicate cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers.

How many shares were sold and at what price?

Propanc Biopharma sold 1,000,000 shares of common stock at $4.00 per share, with the underwriter having a 45-day option to purchase up to 150,000 additional shares.

When did the offering take place and close?

The shares commenced trading on the Nasdaq Capital Market on August 15, 2025, and the offering closed on August 18, 2025.

Who managed the public offering?

D. Boral Capital LLC and Craft Capital Management LLC acted as book running managers for the offering.

What type of cancer treatments is Propanc Biopharma developing?

The company is developing novel proenzyme therapies based on pancreatic enzymes that target and eradicate cancer stem cells to prevent recurrence and metastasis in pancreatic, ovarian, and colorectal cancers.

How do Propanc’s pancreatic proenzymes work against cancer?

The pancreatic proenzymes stimulate biological reactions in the body and represent the body’s primary defense against cancer by targeting and eradicating cancer stem cells that cause recurrence and metastasis.

Where can I find more information about Propanc Biopharma?

For more information, visit www.propanc.com or view the full press release at https://ibn.fm/QxpyL.

What is BioMedWire and its role in this announcement?

BioMedWire is a specialized communications platform focused on biotechnology and biomedical sciences that distributes breaking news and content through its network, providing this announcement to reach investors and the public.